Antiretroviral Resistance and Pregnancy Characteristics of Women with Perinatal and Nonperinatal HIV Infection

Table 3

Antiretroviral drug resistance patterns in HIV-infected pregnant women.

Subject number	NRTI resistance	NNRTI resistance	PI resistance	ARV regimen change during pregnancy	ART prior to delivery
PHIV
1		✓		✓	AZT/3TC, DDI, NVP, NFV
3			✓		FTC/TDF, DRV, RIT
5	✓			✓	FTC/TDF, LPV/RIT
10			✓		ABC/AZT/3TC
12		✓	✓	✓	FTC/TDF, DRV, RIT, T-20
16			✓		FTC/TDF, LPV/RIT
28	✓	✓		✓	ABC/3TC, EFV, DRV, RIT
29		✓			ABC, TDF, LPV/RIT
46		✓			FTC/TDF, RAL
50		✓	✓		ATZ/3TC, LOP/RIT
58	✓	✓			ETV, DRV, RIT, RAL
60	✓	✓	✓	✓	TPV, RIT, MVC, T-20, DTG
77	✓	✓			FTC/TDF, EVG, COB
78	✓	✓			DRV, RIT, RAL, ETV
79		✓			DRV, RIT, FTC/TDF, ABC/3TC
NPHIV
18		✓			AZT/3TC, LPV/RIT
25		✓		✓	AZT/3TC, RAL
56	✓				AZT/3TC, NFV

The genotypic mutation types were not recorded for 3 subjects: 2 PHIV (#80 and 81) and 1 NPHIV (#76). The ART regimens at delivery for these subjects were #80, FTC/TDF/RPV; #81, FTC/ETC/EVG/COB; and #76, ABC/3TC, ETV. #76 required a change in ART during pregnancy. ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; COB, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETV, etravirine; EVG, elvitegravir; FTC, emtricitabine; LPV, lopinavir; MVC, maraviroc; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; RAL, raltegravir; RIT, ritonavir, RPV, rilpivirine; T-20, enfuvirtide.